ClinicalTrials.gg
CompletedNCT02564718Einstein JrUpdated Jul 10, 2018Results posted

Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates

A Phase 1/2 interventional study of Rivaroxaban (Xarelto, BAY59-7939) in Thromboembolism, sponsored by Bayer. Completed at 9 sites in 7 countries. Open to participants aged Up to 6 Months. Per ClinicalTrials.gov, last updated 2018-07-10.

Sponsored by Bayer · Phase 1/2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
Up to 6 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing rivaroxaban in Thromboembolism — 4 open to participants now, 4 under way, 1 of them phase 3. Rivaroxaban · Thromboembolism.

Enrollment
16th of 17
10 · median 112
Started
2015
the only one that year
Phase 1/2
Only one
of the 17
Registered
10th of 17
by date
Lead sponsor
8 of 17
Bayer

Among the 17 studies testing rivaroxaban in Thromboembolism, this one is the 16th largest by enrollment, is the only one that started in 2015, is the only one in phase 1/2, and was the 10th registered.

Thromboembolism

288 studies on the registry are indexed under Thromboembolism; 42 are open to participants now.

Browse Thromboembolism studies →

Open to participants now

4 of the 17 studies testing rivaroxaban in Thromboembolism are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 32 Thromboembolism studies recruiting now, 23 (72%) set no upper age limit and 4 (13%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: Up to 6 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing rivaroxaban in Thromboembolism, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether rivaroxaban is safe and effective to use in children age newborn to less than 6 months and how long it stays in the body and how it is used in the body. Safety will be assessed by looking at the incidence and types of bleeding events. There will also be a check for worsening of blood clots.

Read the detailed description

Neonates and infants aged less than 6 months who pass the screen of in- and exclusion criteria, who have been treated for at least five days with heparin and /or vitamin K antagonist (VKA) for confirmed symptomatic or asymptomatic arterial or venous thrombosis are eligible for the study. Study treatment consists of a 7-day treatment with an age- and body weight-adjusted three times daily, approximately 8 hours apart oral rivaroxaban dosing to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban once daily. Rivaroxaban will be provided as granules for preparation of an oral suspension (1 mg/mL after re-suspension) using a t.i.d. regimen with 8-hour intervals. An ultrasound will be performed before starting rivaroxaban at treatment day 1 and after the end of rivaroxaban treatment at day 8. The last dose of rivaroxaban treatment will be followed by a 30-day post study treatment period, regardless of the duration of study drug administration. After cessation of rivaroxaban, it is at the investigator's discretion to continue with anticoagulants. The principal safety outcome is the combination of major and clinically relevant non-major bleeding. The efficacy outcome is the composite of all symptomatic recurrent thromboembolism and asymptomatic deterioration in thrombotic burden on repeat imaging. All suspected recurrent thromboembolism, asymptomatic deterioration in thrombotic burden on repeat imaging, deaths, as well as all episodes of bleeding will be evaluated by a central independent adjudication committee (CIAC). Adjudication results will be the basis for the final analyses.

For all children, visits are scheduled at regular time points (see Table 1). Enrolled children who are not treated or those with premature discontinuation of rivaroxaban will at least be seen at the end of the study treatment period. During all contacts, the treatment and clinical course of the child will be evaluated. Children with suspected efficacy or safety outcomes will undergo confirmatory testing as per standard of care. Blood samples for pharmacokinetic (PK)/pharmacodynamics (PD) will be taken at defined time points (see Table 2).

An Independent Data Monitoring Committee (DMC) will monitor the children's safety during the study and give recommendations to the steering committee.

03

Conditions studied

  • Thromboembolism

Browse trials for

Keywords

  • Pediatric
04

Who can participate

Ages eligible
Up to 6 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children from birth to less than 6 months with documented symptomatic or asymptomatic venous or arterial thrombosis who have been treated with anticoagulant therapy for at least 5 days.
  • Gestational age at birth of at least 37 weeks.
  • , , creatinine, and total and direct assessed within 10 days prior to enrollment.
  • Oral feeding/nasogastric/gastric feeding for at least 10 days.
  • provided.
  • Body weight >2600 g

Exclusion criteria

Exclusion Criteria:

  • Active bleeding or high risk for bleeding contraindicating anticoagulant therapy, including history of intra-ventricular bleeding.
  • Symptomatic progression of thrombosis during preceding anticoagulant treatment.
  • Planned invasive procedures, including lumbar puncture and removal of non-peripherally placed central lines during study treatment.
  • Hepatic disease which is associated with either: coagulopathy leading to a bleeding risk, or (ALT) > 5x upper level of normal () or total (TB) > 2x ULN with direct bilirubin > 20% of the total.
  • Creatinine >1.5 times of normal.
  • Uncontrolled Hypertension defined as >95th percentile.
  • History of gastrointestinal disease or surgery associated with impaired absorption.
  • count \<100 x 109/L.
  • Concomitant use of strong inhibitors of both cytochrome P450 isoenzyme 3A4 () and P-glycoprotein (P-gp), e.g. all protease inhibitors and the following azole-antimycotics agents: ketoconazole, itraconazole, voriconazole, posaconazole, if used systemically (fluconazole is allowed)
  • Concomitant use of strong inducers of CYP3A4, e.g. rifampicin, rifabutin, phenobarbital, phenytoin and carbamazepine
  • Indication for anticoagulant therapy other than current thrombosis.
  • Indication for antiplatelet therapy or non- anti-inflammatory drug (NSAID) therapy. Incidental use is allowed.
  • to rivaroxaban or its .
  • Participation in a study with an drug or medical device within 30 days prior to enrollment.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Arm 1

    Rivaroxaban oral suspension from granules will be dosed according to body weight as oral 0.1% suspension (1 mg/mL)

    Drug: Rivaroxaban (Xarelto, BAY59-7939)

Interventions

  • Body weight adjusted dosing of rivaroxaban to achieve a similar exposure in the range as that observed in adults treated for venous thromboembolism (VTE) with 20 mg once daily.

06

What researchers measure

Primary outcomes

  1. Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 1

    Concentration of pharmacokinetic parameters of rivaroxaban in plasma was evaluated.

    Time frame: 30 minutes to 1.5 hours post-dose; 2 to 4 hours post-dose (bid dosing) and 30 minutes to 3 hours post-dose; 7 to 8 hours post-dose on Day 1 (tid dosing)

  2. Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 3

    Concentration of pharmacokinetic parameters of rivaroxaban in plasma was evaluated.

    Time frame: 2 to 8 hours post-dose (bid dosing) and 30 minutes to 3 hours post-dose; 7 to 8 hours post-dose on Day 3 (tid dosing)

  3. Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 8

    Concentration of pharmacokinetic parameters of rivaroxaban in plasma was evaluated.

    Time frame: 10 to 16 hours post-dose on Day 8 (bid dosing)

  4. Change From Baseline in Prothrombin Time at Day 1

    Prothrombin time is a global clotting test used for the assessment of the extrinsic pathway of the blood coagulation cascade.

    Time frame: 10-16 hours post-dose on Day 8 (baseline), 2-4 hours after the first dose on Day 1 (bid dosing) and 7-8 hours after the first dose on Day 1 (tid dosing)

  5. Change From Baseline in Prothrombin Time at Day 3

    Prothrombin time is a global clotting test used for the assessment of the extrinsic pathway of the blood coagulation cascade.

    Time frame: 10-16 hours post-dose on Day 8 (baseline), 2-8 hours post-dose on Day 3 (bid dosing) and 0.5-3 hours post-dose on Day 3 (tid dosing)

  6. Change From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 1

    The Activated partial thromboplastin time (aPTT) is a screening test for the intrinsic pathway and is sensitive for deficiencies of factors I, II, V, VIII, IX, X, XI and XII.

    Time frame: 10-16 hours post-dose on Day 8 (baseline), 2-4 hours after the first dose on Day 1 (bid dosing) and 7-8 hours after the first dose on Day 1 (tid dosing)

  7. Change From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 3

    The Activated partial thromboplastin time (aPTT) is a screening test for the intrinsic pathway and is sensitive for deficiencies of factors I, II, V, VIII, IX, X, XI and XII.

    Time frame: 10-16 hours post-dose on Day 8 (baseline), 2-8 hours post-dose on Day 3 (bid dosing) and 0.5-3 hours post-dose on Day 3 (tid dosing)

  8. Anti-factor Xa Activity (Anti-Xa) Values at Day 1

    The individual anti-Factor Xa activity was determined ex-vivo using a photometric method.

    Time frame: 2-4 hours after the first dose on Day 1 (bid dosing) and 7-8 hours after the first dose on Day 1 (tid dosing)

  9. Anti-factor Xa Activity (Anti-Xa) Values at Day 3

    The individual anti-Factor Xa activity was determined ex-vivo using a photometric method.

    Time frame: 2-8 hours post-dose on Day 3 (bid dosing) and 0.5-3 hours post-dose on Day 3 (tid dosing)

  10. Anti-factor Xa Activity (Anti-Xa) Values at Day 8

    The individual anti-Factor Xa activity was determined ex-vivo using a photometric method.

    Time frame: 10-16 hours post-dose on Day 8 (both bid and tid dosing)

Secondary outcomes

  1. Number of Participants With Major and Clinically Relevant Non-Major Bleeding Events

    Central independent adjudication committee (CIAC) classified bleeding as follows: Major bleeding is defined as overt bleeding and •associated with a fall in hemoglobin of 2 gram/deciliter (g/dL) or more, •leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or •occurring in a critical site, example: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or •contributing to death. Clinically relevant non-major bleeding is defined as overt bleeding not meeting the criteria for major bleeding, but associated with: •medical intervention, or •unscheduled contact (visit or telephone call) with a physician, or •cessation (temporary) of study treatment, or •discomfort for the child such as pain

    Time frame: From start of study drug administration until 30-day post study treatment period

  2. Number of Participants With Symptomatic Recurrent Venous Thromboembolism and Asymptomatic Deterioration in Thrombotic Burden on Repeat Imaging

    Symptomatic recurrence of thromboembolism and asymptomatic deterioration was documented using the appropriate imaging test and confirmed by CIAC which was unaware of treatment assignment. Asymptomatic deterioration in thrombotic burden on repeat imaging, as assessed by the CIAC. Adjudication results were the basis for the final analyses.

    Time frame: From start of study drug administration until 30-day post study treatment period

07

Results

Posted Jul 10, 2018

Participant flow

Study was conducted at 9 study centers in 7 countries between 19 November 2015 (first participant first visit) and 18 December 2017 (last participant last visit).

Participant flow — Overall Study
MilestoneRivaroxaban (BAY59-7939) Suspension BidRivaroxaban (BAY59-7939) Suspension Tid
Started55
Completed54
Not completed01
Withdrew: Withdrew from treatment01

Outcome measures

PrimaryConcentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 1

Concentration of pharmacokinetic parameters of rivaroxaban in plasma was evaluated.

Time frame:
30 minutes to 1.5 hours post-dose; 2 to 4 hours post-dose (bid dosing) and 30 minutes to 3 hours post-dose; 7 to 8 hours post-dose on Day 1 (tid dosing)
Reported as:
Geometric mean · microgram per liter (mcg/L)
Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 1
microgram per liter (mcg/L)Rivaroxaban (BAY59-7939) Suspension BidRivaroxaban (BAY59-7939) Suspension Tid
30 minutes to 1.5 hours post-dose85.2001 ± 37.72—
30 minutes to 3 hours post-dose—42.6837 ± 39.35
2 to 4 hours post-dose73.7641 ± 64.38—
7 to 8 hours post-dose—12.1027 ± 130.13
SecondaryNumber of Participants With Major and Clinically Relevant Non-Major Bleeding Events

Central independent adjudication committee (CIAC) classified bleeding as follows: Major bleeding is defined as overt bleeding and •associated with a fall in hemoglobin of 2 gram/deciliter (g/dL) or more, •leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or •occurring in a critical site, example: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or •contributing to death. Clinically relevant non-major bleeding is defined as overt bleeding not meeting the criteria for major bleeding, but associated with: •medical intervention, or •unscheduled contact (visit or telephone call) with a physician, or •cessation (temporary) of study treatment, or •discomfort for the child such as pain

Time frame:
From start of study drug administration until 30-day post study treatment period
Reported as:
Number · count of participants
Number of Participants With Major and Clinically Relevant Non-Major Bleeding Events
count of participantsRivaroxaban (BAY59-7939) Suspension BidRivaroxaban (BAY59-7939) Suspension Tid
Major bleeding events00
Clinically relevant non-major bleeding events00
SecondaryNumber of Participants With Symptomatic Recurrent Venous Thromboembolism and Asymptomatic Deterioration in Thrombotic Burden on Repeat Imaging

Symptomatic recurrence of thromboembolism and asymptomatic deterioration was documented using the appropriate imaging test and confirmed by CIAC which was unaware of treatment assignment. Asymptomatic deterioration in thrombotic burden on repeat imaging, as assessed by the CIAC. Adjudication results were the basis for the final analyses.

Time frame:
From start of study drug administration until 30-day post study treatment period
Reported as:
Number · count of participants
Number of Participants With Symptomatic Recurrent Venous Thromboembolism and Asymptomatic Deterioration in Thrombotic Burden on Repeat Imaging
count of participantsRivaroxaban (BAY59-7939) Suspension BidRivaroxaban (BAY59-7939) Suspension Tid
Symptomatic recurrent venous thromboembolism00
Asymptomatic deterioration in thrombotic burden00
PrimaryConcentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 3

Concentration of pharmacokinetic parameters of rivaroxaban in plasma was evaluated.

Time frame:
2 to 8 hours post-dose (bid dosing) and 30 minutes to 3 hours post-dose; 7 to 8 hours post-dose on Day 3 (tid dosing)
Reported as:
Geometric mean · microgram per liter (mcg/L)
Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 3
microgram per liter (mcg/L)Rivaroxaban (BAY59-7939) Suspension BidRivaroxaban (BAY59-7939) Suspension Tid
30 minutes to 3 hours post-dose—32.2879 ± 267.05
2 to 8 hours post-dose102.3285 ± 40.36—
7 to 8 hours post-dose—9.1716 ± 160.52
PrimaryConcentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 8

Concentration of pharmacokinetic parameters of rivaroxaban in plasma was evaluated.

Time frame:
10 to 16 hours post-dose on Day 8 (bid dosing)
Reported as:
Geometric mean · microgram per liter (mcg/L)
Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 8
microgram per liter (mcg/L)Rivaroxaban (BAY59-7939) Suspension BidRivaroxaban (BAY59-7939) Suspension Tid
Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 82.5696 ± 70.82NA ± NA
PrimaryChange From Baseline in Prothrombin Time at Day 1

Prothrombin time is a global clotting test used for the assessment of the extrinsic pathway of the blood coagulation cascade.

Time frame:
10-16 hours post-dose on Day 8 (baseline), 2-4 hours after the first dose on Day 1 (bid dosing) and 7-8 hours after the first dose on Day 1 (tid dosing)
Reported as:
Mean · seconds (sec)
Change From Baseline in Prothrombin Time at Day 1
seconds (sec)Rivaroxaban (BAY59-7939) Suspension BidRivaroxaban (BAY59-7939) Suspension Tid
Change From Baseline in Prothrombin Time at Day 111.6 ± 17.30.025 ± 0.714
PrimaryChange From Baseline in Prothrombin Time at Day 3

Prothrombin time is a global clotting test used for the assessment of the extrinsic pathway of the blood coagulation cascade.

Time frame:
10-16 hours post-dose on Day 8 (baseline), 2-8 hours post-dose on Day 3 (bid dosing) and 0.5-3 hours post-dose on Day 3 (tid dosing)
Reported as:
Mean · seconds (sec)
Change From Baseline in Prothrombin Time at Day 3
seconds (sec)Rivaroxaban (BAY59-7939) Suspension BidRivaroxaban (BAY59-7939) Suspension Tid
Change From Baseline in Prothrombin Time at Day 33.74 ± 2.841.13 ± 2.10
PrimaryChange From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 1

The Activated partial thromboplastin time (aPTT) is a screening test for the intrinsic pathway and is sensitive for deficiencies of factors I, II, V, VIII, IX, X, XI and XII.

Time frame:
10-16 hours post-dose on Day 8 (baseline), 2-4 hours after the first dose on Day 1 (bid dosing) and 7-8 hours after the first dose on Day 1 (tid dosing)
Reported as:
Mean · seconds (sec)
Change From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 1
seconds (sec)Rivaroxaban (BAY59-7939) Suspension BidRivaroxaban (BAY59-7939) Suspension Tid
Change From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 113.6 ± 12.42.33 ± 5.53
PrimaryChange From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 3

The Activated partial thromboplastin time (aPTT) is a screening test for the intrinsic pathway and is sensitive for deficiencies of factors I, II, V, VIII, IX, X, XI and XII.

Time frame:
10-16 hours post-dose on Day 8 (baseline), 2-8 hours post-dose on Day 3 (bid dosing) and 0.5-3 hours post-dose on Day 3 (tid dosing)
Reported as:
Mean · seconds (sec)
Change From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 3
seconds (sec)Rivaroxaban (BAY59-7939) Suspension BidRivaroxaban (BAY59-7939) Suspension Tid
Change From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 37.02 ± 5.083.47 ± 7.59
PrimaryAnti-factor Xa Activity (Anti-Xa) Values at Day 1

The individual anti-Factor Xa activity was determined ex-vivo using a photometric method.

Time frame:
2-4 hours after the first dose on Day 1 (bid dosing) and 7-8 hours after the first dose on Day 1 (tid dosing)
Reported as:
Mean · microgram per liter (mcg/L)
Anti-factor Xa Activity (Anti-Xa) Values at Day 1
microgram per liter (mcg/L)Rivaroxaban (BAY59-7939) Suspension BidRivaroxaban (BAY59-7939) Suspension Tid
Anti-factor Xa Activity (Anti-Xa) Values at Day 163.3 ± 60.818.0 ± 8.37
PrimaryAnti-factor Xa Activity (Anti-Xa) Values at Day 3

The individual anti-Factor Xa activity was determined ex-vivo using a photometric method.

Time frame:
2-8 hours post-dose on Day 3 (bid dosing) and 0.5-3 hours post-dose on Day 3 (tid dosing)
Reported as:
Mean · microgram per liter (mcg/L)
Anti-factor Xa Activity (Anti-Xa) Values at Day 3
microgram per liter (mcg/L)Rivaroxaban (BAY59-7939) Suspension BidRivaroxaban (BAY59-7939) Suspension Tid
Anti-factor Xa Activity (Anti-Xa) Values at Day 367.3 ± 48.759.8 ± 46.8
PrimaryAnti-factor Xa Activity (Anti-Xa) Values at Day 8

The individual anti-Factor Xa activity was determined ex-vivo using a photometric method.

Time frame:
10-16 hours post-dose on Day 8 (both bid and tid dosing)
Reported as:
Mean · microgram per liter (mcg/L)
Anti-factor Xa Activity (Anti-Xa) Values at Day 8
microgram per liter (mcg/L)Rivaroxaban (BAY59-7939) Suspension BidRivaroxaban (BAY59-7939) Suspension Tid
Anti-factor Xa Activity (Anti-Xa) Values at Day 87.25 ± 0.009.92 ± 5.35

Adverse events

Collected over From start of study treatment up to 30 days after the last administration of study drug. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rivaroxaban (BAY59-7939) Suspension Bid0/5 (0%)0/5 (0%)1/5 (20%)
Rivaroxaban (BAY59-7939) Suspension Tid0/5 (0%)1/5 (20%)0/5 (0%)
Most frequent serious events
Most frequent serious events
EventRivaroxaban (BAY59-7939) Suspension BidRivaroxaban (BAY59-7939) Suspension Tid
Atrial thrombosisCardiac disorders0/51/5
Most frequent other events
Most frequent other events
EventRivaroxaban (BAY59-7939) Suspension BidRivaroxaban (BAY59-7939) Suspension Tid
VomitingGastrointestinal disorders1/50/5

Baseline characteristics

Safety analysis set (SAF) included all participants who received at least one dose of rivaroxaban.

Age, Continuous
Age, Continuous(Months)Rivaroxaban (BAY59-7939) Suspension BidRivaroxaban (BAY59-7939) Suspension TidTotal
Mean1.81 ± 2.241.12 ± 0.601.47 ± 1.59
Sex: Female, Male
Sex: Female, Male(Participants)Rivaroxaban (BAY59-7939) Suspension BidRivaroxaban (BAY59-7939) Suspension TidTotal
Female145
Male415
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Rivaroxaban (BAY59-7939) Suspension BidRivaroxaban (BAY59-7939) Suspension TidTotal
Black or African American101
White358
Unknown or Not Reported101
Weight
Weight(Kilogram (kg))Rivaroxaban (BAY59-7939) Suspension BidRivaroxaban (BAY59-7939) Suspension TidTotal
Mean4.33 ± 2.193.70 ± 0.854.02 ± 1.60
Prothrombin Time
Prothrombin Time(Seconds (sec))Rivaroxaban (BAY59-7939) Suspension BidRivaroxaban (BAY59-7939) Suspension TidTotal
Mean13.3 ± 0.37813.9 ± 1.31NA ± NA
Activated Partial Thromboplastin Time (aPTT)
Activated Partial Thromboplastin Time (aPTT)(Seconds (sec))Rivaroxaban (BAY59-7939) Suspension BidRivaroxaban (BAY59-7939) Suspension TidTotal
Mean34.0 ± 4.0534.9 ± 2.62NA ± NA
08

Study locations

9 sites
  • Wien, 1090, Austria
  • Montpellier, 34059, France
  • Erlangen, 91052, Germany
  • Ramat Gan, 5262000, Israel
  • Milano, Lombardia 20122, Italy
  • Barcelona, 08035, Spain
  • Madrid, 28007, Spain
  • Madrid, 28046, Spain
  • Izmir, 35-100, Turkey
09

References and documents

Publications

  • Monagle P, Lensing AWA, Thelen K, Martinelli I, Male C, Santamaria A, Samochatova E, Kumar R, Holzhauer S, Saracco P, Simioni P, Robertson J, Grangl G, Halton J, Connor P, Young G, Molinari AC, Nowak-Gottl U, Kenet G, Kapsa S, Willmann S, Pap AF, Becka M, Twomey T, Beyer-Westendorf J, Prins MH, Kubitza D; EINSTEIN-Jr Phase 2 Investigators. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematol. 2019 Oct;6(10):e500-e509. doi: 10.1016/S2352-3026(19)30161-9. Epub 2019 Aug 13. PubMed 31420317 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2015 to primary completion in Dec 2017, 24 months.

Results were first posted in Jul 2018, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2015
First posted
Oct 1, 2015
StartActual
Nov 19, 2015
Primary completionActual
Dec 18, 2017
CompletionActual
Dec 18, 2017
Results first posted
Jul 10, 2018
Last update
Jul 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02564718
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Oct 1, 2015
Start date
Nov 19, 2015
Primary completion
Dec 18, 2017
Completion
Dec 18, 2017
Results posted
Jul 10, 2018
Last update
Jul 10, 2018

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion